CONOR RECEIVES EU APPROVAL FOR DRUG-ELUTING

Conor Medsystem, maker of a next-generation drug-eluting stent, received Conformite European (CE) Mark approval for its CoStar cobalt chromium paclitaxel-eluting stent for the treatment of coronary artery disease.

This means the system will immediately be marketed and distributed in the European Union and other countries accepting the CE mark.

In contrast to conventional surface-coasted stents, Conor's stent is designed for vascular drug delivery and is not coated. Conor's stent has hundreds of small holes, each acting as a reservoir into which drug-polymer compositions can be loaded.